# Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy

> **NCT01513408** · NA · UNKNOWN · sponsor: **Centre Georges Francois Leclerc** · enrollment: 500 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio

## Key facts

- **NCT ID:** NCT01513408
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2015-10
- **Final completion:** 2025-10
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513408, "Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01513408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*